We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) has introduced biobased films that can help reduce the climate impact on the manufacturing of therapies, thereby increasing the sustainability of biologics therapies development. The first-of-its-kind solutions build on the company’s existing Aegis and CX film offerings that are widely used and validated by customers.
The company is helping biopharma manufacturers reduce their environmental impact without having to validate new bioprocessing containers (BPCs), thus helping them speed up treatment deliveries. The recent development is also likely to enhance its BioProduction business under the Life Science Solutions segment.
More on the News
Instead of fossil fuel materials, Thermo Fisher has leveraged plant-based materials to deliver lower-carbon, biobased films for its single-use technology BPCs. This enables customers to maintain consistency in their BPCs while also achieving a reduction in greenhouse gas (GHG) emissions. By adopting these biobased, sustainable films, they can eliminate carbon emissions coming from the plastic resin.
The biobased films have earned an International Sustainability and Carbon Certification (“ISCC”) PLUS certification, a top global certification for circular and biobased products. Biopharma manufacturers can now pre-purchase the biobased films to incorporate into their upstream or downstream system in early 2025. Thermo Fisher will also help customers as they monitor their carbon reduction quantities and support their sustainability objectives.
Image Source: Zacks Investment Research
In addition to offering BPCs with biobased film, Thermo Fisher connects customers with recyclers to facilitate the recycling of BPCs post-use. This program helps biopharma manufacturers to divert waste from landfills or carbon-intensive incineration, advancing their sustainability goals through a convenient recycling service that turns BPCs into high-quality plastic lumber. Since the initiation of the program, approximately 400,000 pounds of plastic waste have been diverted from landfills or incineration.
Significance of Sustainability Efforts
The company is exploring new ways to design, produce, package and ship products to reduce the environmental impacts of the industry while still maintaining the expected quality and performance. Thermo Fisher also showcased further commitment to sustainable practices and responsible manufacturing by earning an ISCC PLUS certification for producing biobased resins in its Nunc Cell Factory product line, which is used in the development of vaccines and biologics.
These latest innovations and initiatives are intended to help Thermo Fisher’s customers drive sustainability as they tackle some of the most challenging medical issues in the world. The company focuses on five key areas of environmental impact for greener innovation, which are minimizing the use of hazardous materials, reducing waste and using fewer resources, increasing energy efficiency, responsibly packaging and shipping and extending the useful life of products and materials.
The scientists at Thermo Fisher apply Design for Sustainability principles to design products, creating more sustainable options as part of its Greener by Design portfolio to help advance sustainability and improve lab safety.
Industry Prospects
Per a Precedence Research report, the global bio-based packaging market was valued at $7.92 billion in 2022 and is expected to witness a CAGR of 12.6% up to 2032.
Plant-based materials like cellulose nanocrystals and biopolymers can replace non-recyclable layers in plastic packaging to improve recyclability. Consumers and the government support the use of bio-based packaging and coatings to reduce plastic waste.
Recent Developments in the Life Science Solutions Division
Last month, Thermo Fisher expanded the Thermo Scientific KingFisher instrument portfolio with PlasmidPro Maxi Processor (PlasmidPro). The system enables innovation at scale by providing complete automation across mini and maxi-scale purification and delivering high-purity plasmids without manual column preparation and intervention. The company’s new “press and go” solution accelerates the purification process, catering to the rapidly growing demand for plasmid DNA purification for emerging therapies.
Price Performance
In the past year, TMO shares have rallied 2.8% compared with the industry’s rise of 3.1%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Hims & Hers Heath shares have surged 132.8% in the past year. Estimates for the company’s earnings have increased from 19 cents to 20 cents in 2024 and from 35 cents to 38 cents in 2025 in the past seven days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for ResMed’s fiscal 2024 earnings per share have remained constant at $7.70 in the past 30 days. Shares of the company have plunged 11.8% in the past year compared with the industry’s decline of 2.2%.
RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
Estimates for Medpace’s 2024 earnings per share have remained constant at $11.29 in the past 30 days. Shares of the company have surged 69.2% in the past year compared with the industry’s 5.3% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs
Thermo Fisher Scientific (TMO - Free Report) has introduced biobased films that can help reduce the climate impact on the manufacturing of therapies, thereby increasing the sustainability of biologics therapies development. The first-of-its-kind solutions build on the company’s existing Aegis and CX film offerings that are widely used and validated by customers.
The company is helping biopharma manufacturers reduce their environmental impact without having to validate new bioprocessing containers (BPCs), thus helping them speed up treatment deliveries. The recent development is also likely to enhance its BioProduction business under the Life Science Solutions segment.
More on the News
Instead of fossil fuel materials, Thermo Fisher has leveraged plant-based materials to deliver lower-carbon, biobased films for its single-use technology BPCs. This enables customers to maintain consistency in their BPCs while also achieving a reduction in greenhouse gas (GHG) emissions. By adopting these biobased, sustainable films, they can eliminate carbon emissions coming from the plastic resin.
The biobased films have earned an International Sustainability and Carbon Certification (“ISCC”) PLUS certification, a top global certification for circular and biobased products. Biopharma manufacturers can now pre-purchase the biobased films to incorporate into their upstream or downstream system in early 2025. Thermo Fisher will also help customers as they monitor their carbon reduction quantities and support their sustainability objectives.
Image Source: Zacks Investment Research
In addition to offering BPCs with biobased film, Thermo Fisher connects customers with recyclers to facilitate the recycling of BPCs post-use. This program helps biopharma manufacturers to divert waste from landfills or carbon-intensive incineration, advancing their sustainability goals through a convenient recycling service that turns BPCs into high-quality plastic lumber. Since the initiation of the program, approximately 400,000 pounds of plastic waste have been diverted from landfills or incineration.
Significance of Sustainability Efforts
The company is exploring new ways to design, produce, package and ship products to reduce the environmental impacts of the industry while still maintaining the expected quality and performance. Thermo Fisher also showcased further commitment to sustainable practices and responsible manufacturing by earning an ISCC PLUS certification for producing biobased resins in its Nunc Cell Factory product line, which is used in the development of vaccines and biologics.
These latest innovations and initiatives are intended to help Thermo Fisher’s customers drive sustainability as they tackle some of the most challenging medical issues in the world. The company focuses on five key areas of environmental impact for greener innovation, which are minimizing the use of hazardous materials, reducing waste and using fewer resources, increasing energy efficiency, responsibly packaging and shipping and extending the useful life of products and materials.
The scientists at Thermo Fisher apply Design for Sustainability principles to design products, creating more sustainable options as part of its Greener by Design portfolio to help advance sustainability and improve lab safety.
Industry Prospects
Per a Precedence Research report, the global bio-based packaging market was valued at $7.92 billion in 2022 and is expected to witness a CAGR of 12.6% up to 2032.
Plant-based materials like cellulose nanocrystals and biopolymers can replace non-recyclable layers in plastic packaging to improve recyclability. Consumers and the government support the use of bio-based packaging and coatings to reduce plastic waste.
Recent Developments in the Life Science Solutions Division
Last month, Thermo Fisher expanded the Thermo Scientific KingFisher instrument portfolio with PlasmidPro Maxi Processor (PlasmidPro). The system enables innovation at scale by providing complete automation across mini and maxi-scale purification and delivering high-purity plasmids without manual column preparation and intervention. The company’s new “press and go” solution accelerates the purification process, catering to the rapidly growing demand for plasmid DNA purification for emerging therapies.
Price Performance
In the past year, TMO shares have rallied 2.8% compared with the industry’s rise of 3.1%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS - Free Report) , ResMed (RMD - Free Report) and Medpace (MEDP - Free Report) . While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), ResMed and Medpace carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks Rank #1 stocks here.
Hims & Hers Heath shares have surged 132.8% in the past year. Estimates for the company’s earnings have increased from 19 cents to 20 cents in 2024 and from 35 cents to 38 cents in 2025 in the past seven days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for ResMed’s fiscal 2024 earnings per share have remained constant at $7.70 in the past 30 days. Shares of the company have plunged 11.8% in the past year compared with the industry’s decline of 2.2%.
RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
Estimates for Medpace’s 2024 earnings per share have remained constant at $11.29 in the past 30 days. Shares of the company have surged 69.2% in the past year compared with the industry’s 5.3% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.